Buscar
image du produit
Journal of Allergy and Clinical Immunology

Suscribirse

Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent - 05/06/24

Doi : 10.1016/j.jaci.2024.02.019 
Douglas P. Mack, MD, MSc a, ⁎ , Timothy E. Dribin, MD b, Paul J. Turner, FRCPCH, PhD c, Richard L. Wasserman, MD, PhD d, Mariam A. Hanna, MD e, Marcus Shaker, MD, MSc f, Mimi L.K. Tang, MBBS, PhD, FRACP, FRCPA, FAAAI g, Pablo Rodríguez del Río, MD, PhD h, Brad Sobolewski, MD, MEd i, Elissa M. Abrams, MD, MPH j, Aikaterini Anagnostou, MD, PhD k, Stefania Arasi, MD, PhD l, Sakina Bajowala, MD m, Philippe Bégin, MD, PhD n, Scott B. Cameron, MD, PhD o, Edmond S. Chan, MD, FRCPC p, Sharon Chinthrajah, MD q, Andrew T. Clark, MB, BS, DM r, Paul Detjen, MD s, George du Toit, MBBCh, RCPCH t, Motohiro Ebisawa, MD, PhD u, Arnon Elizur, MD v, Jeffrey M. Factor, MD w, Justin Greiwe, MD x, Jonathan O’B Hourihane, MB, DM y, Sarah W. Hughes, MPAS, PA-C z, Douglas H. Jones, MD aa, Antonella Muraro, MD, PhD bb, Anna Nowak-Wegrzyn, MD, PhD cc, Nandinee B. Patel, MD, PhD dd, Amy M. Scurlock, MD ee, Atul N. Shah, MD, FACAAI, FAAAAI ff, Sayantani B. Sindher, MD gg, Stephen Tilles, MD hh, Brian P. Vickery, MD ii, Julie Wang, MD jj, Hugh H. Windom, MD kk, Matthew Greenhawt, MD, MBA, MSc ll
a Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada 
b Division of Emergency Medicine, Cincinnati Children’s Hospital Medical Center; and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 
c National Heart & Lung Institute, Imperial College London, London, United Kingdom 
d Medical City Children’s Hospital, Dallas, Tex 
e McMaster University, Hamilton, Ontario, Canada 
f Dartmouth-Hitchcock Medical Center; and Geisel School of Medicine at Dartmouth, Lebanon, NH 
g Department of Allergy Immunology, Murdoch Children’s Research Institute; the Department of Paediatrics, University of Melbourne, Australia; and the Department of Allergy and Immunology, the Royal Children’s Hospital Melbourne, Melbourne, Australia 
h Hospital Infantil Universitario Niño Jesús, Madrid, Spain 
i Department of Pediatrics, Division of Emergency Medicine, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 
j Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Canada 
k Texas Children’s Hospital, Baylor College of Medicine, Houston, Tex 
l Pediatric Allergology Unit of the Allergy Diseases Research Area, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy 
m Kaneland Allergy and Asthma Center, North Aurora, Ill 
n Department of Pediatrics, Section of Allergy, CHU Sainte-Justine; and the Department of Medicine, Section of Allergy, CHUM, Montreal, Canada 
o Department of Pediatrics, Division of Allergy and Immunology, University of British Columbia, Vancouver, Canada 
p Department of Pediatrics, Division of Allergy, University of British Columbia, BC Children’s Hospital, Vancouver, Canada 
q Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, Calif 
r Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom 
s Kenilworth Medical, Kenilworth, Ill 
t Department of Paediatric Allergy, Division of Asthma, Allergy and Lung Biology, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, King’s College London; and the Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom 
u National Hospital Organization, Sagamihara National Hospital, Yokosuka, Japan 
v Institute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center; and the Department of Pediatrics, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 
w Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Conn 
x Bernstein Allergy Group; the Department of Internal Medicine, Division of Immunology/Allergy Section, the University of Cincinnati College of Medicine, Cincinnati, Ohio 
y Paediatrics and Child Health, Royal College of Surgeons in Ireland; and Children’s Health Ireland, Dublin, Ireland 
z Dartmouth-Hitchcock Medical Center, Lebanon, NH 
aa Global Food Initiative, Clearfield, Utah 
bb Food Allergy Referral Centre Padua, University Hospital, Padua, Italy 
cc NYU Grossman School of Medicine, Hassenfeld Children’s Hospital, New York; and the Department of Pediatrics, Gastroenterology, and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland 
dd National Heart & Lung Institute, Imperial College London, London, United Kingdom 
ee Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children’s Hospital and Research Institute, Little Rock, Ark 
ff Center for Asthma & Allergy, New York Food Allergy & Wellness, New York, NY 
gg Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif 
hh Aimmune Therapeutics, Brisbane; and the University of Washington, Seattle, Wash 
ii Emory University School of Medicine; and Children’s Healthcare of Atlanta, Atlanta, Ga 
jj Department of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, NY 
kk Windom Asthma Allergy & Sinus, Sarasota, Fla 
ll Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo 

∗Corresponding author: Douglas Paul Mack, MD, MSc, Halton Pediatric Allergy, 5500 N Service Rd, Ste 106, Burlington, Ontario, L7L 6W6, Canada.Halton Pediatric Allergy5500 N Service RdSte 106BurlingtonOntarioL7L 6W6Canada

Abstract

Background

Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included in the preparatory or consent process.

Objective

We developed consensus recommendations about the OIT process considerations and patient-specific factors that should be addressed before initiating OIT and developed a consensus OIT consent process and information form.

Methods

We convened a 36-member Preparing Patients for Oral Immunotherapy (PPOINT) panel of allergy experts to develop a consensus OIT patient preparation, informed consent process, and framework form. Consensus for themes and statements was reached using Delphi methodology, and the consent information form was developed.

Results

The expert panel reached consensus for 4 themes and 103 statements specific to OIT preparatory procedures, of which 76 statements reached consensus for inclusion specific to the following themes: general considerations for counseling patients about OIT; patient- and family-specific factors that should be addressed before initiating OIT and during OIT; indications for initiating OIT; and potential contraindications and precautions for OIT. The panel reached consensus on 9 OIT consent form themes: benefits, risks, outcomes, alternatives, risk mitigation, difficulties/challenges, discontinuation, office policies, and long-term management. From these themes, 219 statements were proposed, of which 189 reached consensus, and 71 were included on the consent information form.

Conclusion

We developed consensus recommendations to prepare and counsel patients for safe and effective OIT in clinical practice with evidence-based risk mitigation. Adoption of these recommendations may help standardize clinical care and improve patient outcomes and quality of life.

El texto completo de este artículo está disponible en PDF.

Key words : Allergy, anaphylaxis, Delphi, food allergy, oral immunotherapy, consent, patient preparation, shared decision making, risk mitigation

Abbreviations used : EoE, OIT, PPOINT, SDM, SU


Esquema


© 2024  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

    •

  • Contenido

    •

Vol 153 - N° 6

P. 1621-1633 - juin 2024 Regresar al número
Artículo precedente Artículo precedente
  • Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy
  • Tarun Keswani, Nicole A. LaHood, Orlee Marini-Rapoport, Bijoya Karmakar, Léna Andrieux, Brian Reese, Sunny L. Sneed, Lars C. Pedersen, Geoffrey A. Mueller, Sarita U. Patil
| Artículo siguiente Artículo siguiente
  • A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination
  • Muhammad B. Khalid, Ellen Zektser, Eric Chu, Min Li, Joanna Utoh, Patrick Ryan, Hanna S. Loving, Roa Harb, Robbie Kattappuram, Lindsay Chatman, Stella Hartono, Estefania Claudio-Etienne, Guangping Sun, Edward P. Feener, Zhongbo Li, Samuel K. Lai, Quang Le, Lawrence B. Schwartz, Jonathan J. Lyons, Hirsh Komarow, Zhao-Hua Zhou, Haniya Raza, Maryland Pao, Karen Laky, Steven M. Holland, Erica Brittain, Pamela A. Frischmeyer-Guerrerio

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta

Aide & support

Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.

Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.